Bradley M Haverkos
Overview
Explore the profile of Bradley M Haverkos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, et al.
Blood Adv
. 2024 Aug;
8(20):5355-5364.
PMID: 39189932
Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement,...
2.
Iyer S, Huen A, Ai W, Jagadeesh D, Lechowicz M, Okada C, et al.
Haematologica
. 2023 Jul;
109(1):209-219.
PMID: 37439343
Tenalisib, a selective phosphoinositide-3-kinase δ/γ, and salt-inducible-kinase-3 inhibitor has shown efficacy and was well-tolerated in patients with T-cell lymphoma (TCL). In vitro studies suggest a synergistic anti-tumor potential for the...
3.
Wang Z, Ma J, Zhang H, Ramakrishna R, Mintzlaff D, Mathes D, et al.
FEBS Open Bio
. 2023 May;
13(7):1309-1319.
PMID: 37157185
Cutaneous T-cell lymphoma (CTCL) encompasses two main subtypes: mycosis fungoides and Sezary syndrome. Global response rates for the systemic treatment of mycosis fungoides and Sezary syndrome are approximately 30%, and...
4.
Major A, Yu J, Shukla N, Che Y, Karrison T, Treitman R, et al.
Blood Adv
. 2023 Apr;
7(16):4528-4538.
PMID: 37026796
Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy...
5.
Major A, Porcu P, Haverkos B
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900160
Extranodal NK/T-cell lymphoma (ENKTL) is an aggressive extranodal non-Hodgkin lymphoma (NHL) with poor outcomes, particularly in advanced-stage and relapsed/refractory disease. Emerging research on molecular drivers of ENKTL lymphomagenesis by next-generation...
6.
Horwitz S, Ansell S, Ai W, Barnes J, Barta S, Brammer J, et al.
J Natl Compr Canc Netw
. 2022 Mar;
20(3):285-308.
PMID: 35276674
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common...
7.
Milgrom S, Haverkos B
Int J Radiat Oncol Biol Phys
. 2021 Nov;
111(5):1105.
PMID: 34793729
No abstract available.
8.
Alderuccio J, Olszewski A, Evens A, Collins G, Danilov A, Bower M, et al.
Blood Adv
. 2021 Jul;
5(14):2852-2862.
PMID: 34283175
Data addressing prognostication in patients with HIV related Burkitt lymphoma (HIV-BL) currently treated remain scarce. We present an international analysis of 249 (United States: 140; United Kingdom: 109) patients with...
9.
Zayac A, Evens A, Danilov A, Smith S, Jagadeesh D, Leslie L, et al.
Haematologica
. 2021 Feb;
106(7):1932-1942.
PMID: 33538152
Central nervous system (CNS) involvement in Burkitt lymphoma (BL) poses a major therapeutic challenge, and the relative ability of contemporary regimens to treat CNS involvement remains uncertain. We described prognostic...
10.
Horwitz S, Ansell S, Ai W, Barnes J, Barta S, Clemens M, et al.
J Natl Compr Canc Netw
. 2020 Nov;
18(11):1460-1467.
PMID: 33152703
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression...